Evelo partners with Univ. of Chicago, options gut microbe immunotherapy; therapy licensed
The University of Chicago granted Evelo Therapeutics an option to exclusively license global rights to a microbiome-based immunotherapy developed by the university's Thomas Gajewski, MD, PhD.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com